Confetto

Healthcare Marketing and Pharma Advertising in MMI Ethics

Practice the MMI now

Free, no sign-up to start.

How to answer MMI ethics stations on direct-to-consumer drug ads, physician endorsements, and product sales, using AMA Code of Medical Ethics and FDA rules.

Practice the MMI now

Free, no sign-up to start.

In Multiple Mini Interview (MMI) stations on healthcare marketing, interviewers test how you weigh patient education and informed consent against financial conflicts of interest, misleading promotion, and patient safety. According to the AAMC, a typical MMI runs nearly two hours across 6 to 10 stations, giving you 2 minutes to prepare and 5 to 8 minutes to talk at each station. Strong answers apply the AMA Code of Medical Ethics and FDA Office of Prescription Drug Promotion (OPDP) rules to keep patient welfare ahead of commercial gain. Sources: AMA Code of Medical Ethics Opinion 9.6.7: Direct-to-Consumer Advertisements of Prescription Drugs, AMA Code of Medical Ethics Opinion 9.6.1: Advertising & Publicity, AMA Code of Medical Ethics Opinion 9.6.4: Sale of Health-Related Products. Last checked November 11, 2026.

What healthcare marketing stations test in an MMI

Developed by McMaster University, the MMI often includes an ethical scenario station on social and policy questions in virtual circuits, while in-person MMIs may pair you with an actor or standardized patient.

The AAMC states that the MMI does not test memorized knowledge. It measures verbal and nonverbal communication, critical thinking, social skills, and teamwork, and interviewers are often more interested in how you think through a prompt than the final answer you give. Raters may include admissions officers, professors, local physicians, and community members.

When an MMI prompt involves pharmaceutical ads, clinic publicity, or product endorsements, the station is testing whether you recognize the core conflict in AMA Opinion 11.2.2: under no circumstances may physicians place their own financial interests above the welfare of their patients. Strong answers weigh the informational value of honest communication against the risks of deception, undue pressure, and overtreatment. To practice these scenarios out loud under a real station clock, Confetto runs timed AI MMI stations with follow-up questions and rubric feedback. Start your free week.

  • Patient-physician trust: AMA Opinion 1.1.1 defines the relationship as a covenant of trust where physicians commit to responding to the needs and promoting the welfare of patients.
  • Patient autonomy and informed consent: AMA Opinion 2.1.1 states that informed consent is fundamental in both ethics and law, and patients have the right to receive information and ask questions to make well-considered decisions about care.
  • Financial conflicts of interest: Under the AMA Code of Medical Ethics, treatment or hospitalization that is willfully excessive or inadequate constitutes unethical practice.
Four common healthcare marketing MMI conflicts and the official rules that govern them
MMI Scenario TypePossible Benefit to WeighPrimary Ethical RiskGoverning AMA or FDA Standard
Direct-to-consumer (DTC) prescription drug adRaises awareness of diseases and informs patients of new tests, drugs, treatments, and devicesUnrealistic expectations, physician conflict of interest, harm to health and safety, and strained trustAMA Opinion 9.6.7 and FDA OPDP fair-balance rules
Clinic advertising, publicity, and testimonialsShares educational background, fee basis, payment methods, and nondeceptive service infoUnjustified medical expectations, unrepresentative patient testimonials, or claims of exclusive curesAMA Opinion 9.6.1 and Opinion 9.6.3 (referral incentives)
Selling or endorsing health-related productsOffers convenience for patients with immediate and pressing needsFinancial conflict of interest, undue pressure on patients, erosion of trust, and demeaning the professionAMA Opinion 9.6.4 and Opinion 9.6.5 (non-health goods)
Industry gifts, speaker pitches, and CMEIndustry collaboration helps drive innovation in patient care and economic well-beingSubtly biasing, or being perceived to bias, professional judgment in patient careAMA Opinion 9.6.2 and Opinion 9.2.7 (CME funding)

Direct-to-consumer (DTC) pharmaceutical advertising

A common MMI prompt places you in a clinic where a patient requests a brand-name medication or scan they saw on television or social media. AMA Code of Medical Ethics Opinion 9.6.7 recognizes that direct-to-consumer advertising may raise awareness about diseases and treatment and help inform patients about available diagnostic tests, drugs, treatments, and devices.

However, the AMA Code of Medical Ethics warns that direct-to-consumer advertising carries the risk of creating unrealistic expectations for patients, generating conflicts of interest for physicians, adversely affecting patients' health and safety, and compromising patient-physician relationships. Similarly, AMA Opinion 9.6.8 notes that diagnostic imaging tests are sometimes marketed directly to consumers before they have been scientifically validated, and states that physicians should advocate for appropriate trials to determine their predictive power, sensitivity, and specificity for target populations.

When an interviewer or standardized patient asks how a physician should handle a patient requesting an advertised drug, test, or device, walk through the steps in AMA Opinion 9.6.7.

  • Remain objective: avoid bias for or against advertised tests, drugs, treatments, and devices.
  • Engage in dialogue: assess and enhance the patient's understanding of the product they saw advertised.
  • Educate on suitability and cost: explain why an advertised product may not fit the patient, and provide cost-effectiveness information about different options.
  • Resist commercial pressure: do not prescribe tests, drugs, or devices that are not clinically indicated.
  • Obtain informed consent: if an advertised item is appropriate, obtain informed consent in keeping with professional standards before prescribing.
  • Deny inappropriate requests: refuse requests for an inappropriate test, drug, or device while keeping the conversation respectful.

FDA oversight and the Bad Ad Program

Within the FDA's Center for Drug Evaluation and Research (CDER), the Office of Prescription Drug Promotion (OPDP) protects public health by helping ensure that prescription drug promotion is truthful, balanced, and accurately communicated. OPDP reviewers examine drug ads and promotional labeling, send written comments to pharmaceutical sponsors, monitor exhibits at major medical meetings and pharmaceutical conventions, and issue Warning Letters or Untitled Letters for false or misleading promotion.

Under FDA oversight, all prescription drug promotion must meet three core rules: it must not be false or misleading, it must have a balance between efficacy and risk information, and it must reveal material facts about the product, including consequences that may result from using the drug. According to OPDP's metrics glossary, pharmaceutical sponsors are required to submit promotional materials to the FDA under cover of Form 2253 prior to dissemination. When sponsors voluntarily submit draft core launch materials for new drugs or new uses, the FDA's goal is to provide comments within 45 days. When healthcare professionals, consumers, drug sponsors, or law firms submit complaints about potentially false or misleading promotion, OPDP's goal is to preliminarily review and acknowledge receipt within 30 calendar days.

The FDA runs the Bad Ad Program to help healthcare providers recognize and report potentially false or misleading prescription drug promotion. The program explicitly includes physicians, physician assistants, nurse practitioners, nurses, pharmacists, pharmacy technicians, and trainees. Because the majority of prescription drug promotion is directed toward healthcare providers, mentioning in an MMI station that even a medical or pharmacy trainee can report a misleading sales pitch or social media ad through the Bad Ad Program (including anonymously at BadAd@fda.gov or 855-RX-BADAD) gives you a concrete systemic step.

Under the AMA's guidance on direct-to-consumer advertising, physicians should also report ads that promote false expectations, fail to enhance consumer education, convey unclear or misleading health messages, fail to refer patients to their physicians, omit the target population at risk, or encourage consumer self-diagnosis and treatment. Common prescription drug promotion violations include:

  • Omitting or downplaying of risk.
  • Overstating the drug's benefits.
  • Failing to present a fair balance of risk and benefit information.
  • Omitting material facts about the drug.
  • Making claims that are not appropriately supported.
  • Misrepresenting data from studies.
  • Making misleading drug comparisons.
  • Misbranding an investigational drug.
What the FDA's Office of Prescription Drug Promotion (OPDP) regulates vs. does not regulate
Promotional CategoryRegulated by OPDP?Details and Appropriate FDA Reporting Channel (per FDA Bad Ad Program)
TV, radio, and print prescription drug adsYesRegulated when made by or on behalf of the drug's manufacturer, packer, or distributor
Internet and social media prescription drug promotionYesRegulated when made by or on behalf of the manufacturer, packer, or distributor
Sales rep and speaker program presentationsYesRegulated by OPDP. Providers and trainees can report issues to BadAd@fda.gov
Over-the-counter (OTC) non-prescription drugsNoHandled by CDER Office of Compliance (General Complaint Box)
Dietary supplementsNoHandled by the Office of Dietary Supplement Programs
Cosmetics and foodNoHandled by the Center for Food Safety and Applied Nutrition (CFSAN)
Medical devicesNoHandled by the Center for Devices and Radiological Health (CDRH)
Compounded drugs, animal drugs, and certain biologicsNoHandled respectively by CDER Office of Compliance Compounding, Center of Veterinary Medicine, and CBER

Clinic advertising, procedure marketing, and patient testimonials

Many MMI prompts ask about a physician or clinic running aggressive billboards, cosmetic procedure marketing, social media campaigns for elective procedures, or patient testimonials. AMA Opinion 9.6.1 states the baseline rule: there are no restrictions on advertising by physicians except those that can be specifically justified to protect the public from deceptive practices.

A physician may publicize themself through any commercial publicity, provided it does not mislead by omitting necessary material information, does not contain false or misleading statements, and does not otherwise operate to deceive. Permissible ads can include the physician's educational background, the basis on which fees are determined (including charges for specific services), available credit or payment methods, and other nondeceptive information. Consistent with federal regulatory standards under Section 5 of the Federal Trade Commission Act, a physician must have a reasonable basis for any claim before placing an ad.

In an MMI station on clinic or procedure marketing, test the prompt against the four deception issues in AMA Opinions 9.6.1 and 9.6.3.

  • Hard-to-understand medical terms or illustrations: because complex terms or illustrations can deceive the public, physicians must design communications in a readily comprehensible manner.
  • Aggressive, high-pressure tactics and guaranteed results: physicians should avoid aggressive, high-pressure advertising that creates unjustified medical expectations. Stating that a physician has cured or successfully treated a large number of cases of a serious ailment is deceptive if it implies a certainty of result.
  • Unrepresentative patient testimonials: patient testimonials about a physician's skill or service quality tend to be deceptive when they do not reflect the results that patients with comparable conditions generally receive. Objective claims about competence must be factually supportable.
  • Claims of exclusive skill or paid patient referrals: because physicians have an ethical obligation to share medical advances, claiming a truly exclusive or unique skill or remedy can be deceptive (unless it is a true statement about a particular geographic area). Under AMA Opinion 9.6.3, word-of-mouth referrals from current patients must be voluntary, and physicians must not offer financial or other valuable incentives to current patients to recruit new patients.

Physician endorsements, selling products in clinic, and industry gifts

Another MMI scenario involves a clinician selling supplements, skincare, or medical gear from the clinic lobby, or endorsing a health brand online for a commission. The AMA Code of Medical Ethics defines health-related products as any products other than prescription items that, according to the manufacturer or distributor, benefit health. It defines selling as dispensing items from the physician's office or website in exchange for money, or endorsing a product that the patient may order or purchase elsewhere that results in remuneration for the physician.

While in-office sales can offer convenience for patients, Opinion 9.6.4 states that selling or endorsing health-related products raises ethical concerns about financial conflict of interest, risks placing undue pressure on the patient, threatens to erode patient trust, undermines the primary obligation to serve patient interests first, and can demean the profession of medicine. For non-health-related goods, AMA Opinion 9.6.5 states that, with limited exceptions, selling non-health-related goods presents a conflict of interest and threatens to erode the primary obligation of physicians to serve patients before themselves.

If a scenario asks whether a physician can ethically sell or endorse a health-related product, apply the five requirements in AMA Opinion 9.6.4 alongside the rules on industry gifts in AMA Opinion 9.6.2.

  • Require peer-reviewed scientific validity: offer only products whose benefit claims are based on unbiased, sound, systematic, and reliable peer-reviewed literature or scientific review.
  • Disclose financial interests and outside options: fully disclose the nature of the financial interest in person or in writing, and inform patients of the availability of the product or equivalent products elsewhere.
  • Limit sales to immediate and pressing needs: for example, supplying crutches so an injured patient does not have to travel to a local pharmacy. Distributing products free of charge or at cost helps eliminate personal gain.
  • Explain risks and limits in plain language: provide understandable information about the risks, benefits, and limits of scientific knowledge regarding the product.
  • Avoid exclusive distributorships: do not enter arrangements that make products available only through physician offices.
  • Refuse improper industry gifts (AMA Opinion 9.6.2): gifts from industry risk subtly biasing, or being perceived to bias, clinical judgment. Physicians must decline cash gifts in any amount from an entity with a direct interest in treatment recommendations, decline any gift with expected or implied reciprocity, and accept in-kind practice gifts only when they are of minimal value and directly benefit patients (such as patient education). Academic and residency programs may accept special funding for trainees to attend educational meetings only if the program selects recipients by independent institutional criteria and distributes funds without specific attribution to sponsors.

How to pace a 2-minute read and 5- to 8-minute marketing ethics station

This pacing plan and self-scoring checklist are written by our team to fit the AAMC's standard MMI window (a 2-minute prep period and a 5- to 8-minute discussion). Use them when you practice with our free MMI timer or review your recorded answers. If you are new to the circuit format, read our MMI practice questions with answers guide and our MMI preparation guide, or review our medical school interview questions guide if your school also runs a traditional interview.

During the 2-minute reading period, jot down three points: the commercial interest vs. patient welfare conflict, who is affected, and whether the item is a prescription drug, an unvalidated diagnostic scan, a clinic service, or a non-prescription product. Then check that your spoken answer hits these five marks:

  • Named both sides of the marketing prompt: acknowledged how advertising or in-office dispensing can inform or convenience patients before explaining the ethical risks.
  • Protected informed consent and objectivity: checked what the patient understands and avoided automatic bias for or against an advertised product.
  • Addressed cost and alternatives: mentioned educating the patient on cost-effectiveness and where to find equivalent options outside the clinic.
  • Drew a clear boundary on conflicts of interest: stated that financial gain, patient referral incentives, or industry gifts cannot drive clinical decisions.
  • Offered a concrete systemic step: when an ad or sales pitch was false or omitted risks, mentioned reporting it through the FDA's Bad Ad Program or to the manufacturer.
Suggested station order for a healthcare marketing MMI scenario (our team's plan)
Station WindowPhaseWhat to Cover
2-minute prep periodReading timeSpot the product type (Rx drug, diagnostic scan, clinic procedure, or non-Rx product) and name the financial conflict vs. patient welfare tension.
Opening (5- to 8-minute discussion)Open and frameRestate the scenario and note both the legitimate benefit (disease awareness or patient convenience) and the risk to the covenant of trust.
Middle (5- to 8-minute discussion)Gather facts and exploreAsk what the patient understands, check if claims are backed by peer-reviewed evidence, and compare cost-effective alternatives.
Decision (5- to 8-minute discussion)Commit to a decisionState your action: educate and deny an unindicated Rx, require full financial disclosure and at-cost pricing, or remove a deceptive testimonial.
Close and follow-upsSystemic step and follow-upsMention reporting false Rx promotion via the FDA Bad Ad Program and answer the interviewer's follow-up pushback.

Practice question

Practice MMI station and example answer: A patient comes to your primary care clinic requesting a newly advertised prescription drug she saw in a social media video. The drug is not clinically indicated for her condition, and the video she shows you highlights rapid symptom relief without mentioning any warnings or side effects. How should the physician handle this visit?

See an example answer

This scenario puts a patient's proactive interest in her health up against patient safety, clinical judgment, and misleading drug promotion. Direct-to-consumer advertising can be useful when it raises awareness about conditions and prompts patients to seek care, so I would start by welcoming her question rather than dismissing the video. First, I would remain objective and ask what she understood from the ad and what symptoms are bothering her most. That protects the covenant of trust between patient and physician. Next, I would explain in plain language why this specific drug is not suitable or safe for her condition, and walk through proven, cost-effective alternatives so she can make an informed decision about an appropriate treatment plan. As a physician, I cannot let commercial pressure push me into prescribing a medication that is not clinically indicated, so I would respectfully say no to the request even if she feels disappointed. Finally, because a prescription drug ad on social media needs to balance benefits with risks and explain warnings and side effects, I would report the misleading video to the FDA through its Bad Ad Program.

Example answer written by our team. The applicant is invented. It works because it acknowledges the educational upside of direct-to-consumer ads first, follows the exact clinical steps in AMA Opinion 9.6.7 (objectivity, dialogue, cost-effective alternatives, and refusing an unindicated drug), and adds a concrete regulatory step by naming the FDA's Bad Ad Program. To practice stations like this out loud, Start your free week.

Frequently asked questions

What are the ethical pros and cons of direct-to-consumer (DTC) pharmaceutical advertising?

Under AMA Code of Medical Ethics Opinion 9.6.7, direct-to-consumer advertising can raise awareness about diseases and inform patients about available diagnostic tests, drugs, treatments, and devices. However, it also risks creating unrealistic expectations for patients, conflicts of interest for physicians, harm to patient health and safety, and damage to patient-physician relationships.

How should a physician respond when a patient requests an advertised drug?

According to AMA Opinion 9.6.7, the physician should remain objective without automatic bias for or against the advertised product, engage in dialogue to assess and build the patient's understanding, and educate them on suitability and the cost-effectiveness of alternatives. Physicians must resist commercial pressure, obtain informed consent when a product is appropriate, and deny requests for inappropriate tests, drugs, or devices.

Is it ethical for physicians to sell or endorse health-related products?

AMA Opinion 9.6.4 states that selling non-prescription health-related products or endorsing them for remuneration creates financial conflicts of interest and risks placing undue pressure on patients. Physicians who choose to sell health-related products must rely on unbiased peer-reviewed scientific evidence, fully disclose their financial interest, tell patients where to find equivalent products elsewhere, avoid exclusive distributorships, and limit sales to immediate and pressing patient needs.

What are the AMA rules on physician advertising, testimonials, and referral incentives?

AMA Opinion 9.6.1 permits physician advertising as long as it is readily comprehensible, truthful, and not deceptive. Patient testimonials are deceptive when they do not reflect the results that patients with comparable conditions generally receive, and AMA Opinion 9.6.3 prohibits offering financial or other valuable incentives to current patients to recruit new patients.

How can healthcare providers and trainees report misleading prescription drug ads?

Through the FDA's Bad Ad Program, run by the Office of Prescription Drug Promotion (OPDP), physicians, pharmacists, nurses, physician assistants, pharmacy technicians, and trainees can report potentially false or misleading prescription drug promotion by emailing BadAd@fda.gov or calling 855-RX-BADAD. Reports can be made anonymously, and OPDP's goal is to preliminarily review and acknowledge complaints within 30 calendar days.

Sources